27799-83-3

Usage

Uses

Used in Scientific Research:
5-Amino-1-methyl-1H-benzotriazole is used as a research chemical for its unique properties and reactivity in specific chemical reactions. It aids in the development of new compounds and materials, contributing to advancements in various scientific fields.
Used in Industrial Applications:
In the chemical industry, 5-Amino-1-methyl-1H-benzotriazole is used as a catalyst or intermediate in the synthesis of various compounds. Its unique structure and reactivity make it valuable in the production of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Development:
5-Amino-1-methyl-1H-benzotriazole is employed as a building block in the development of new pharmaceuticals. Its unique chemical properties allow it to be incorporated into drug molecules, potentially enhancing their efficacy and selectivity in treating various diseases.
Used in Analytical Chemistry:
5-Amino-1-methyl-1H-benzotriazole is utilized as a reagent in analytical chemistry for the detection and quantification of specific elements or compounds. Its unique chemical properties enable selective reactions, making it a valuable tool in analytical techniques.
Used in Material Science:
5-Amino-1-methyl-1H-benzotriazole is used in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity. Its incorporation into materials can lead to advancements in areas like polymer science, nanotechnology, and materials engineering.

InChI:InChI=1/C7H8N4/c1-11-7-3-2-5(8)4-6(7)9-10-11/h2-4H,8H2,1H3

Upstream product

• 25877-34-3 1-methyl-5-nitro-1H-benzo[d][1,2,3]triazole 
• 2338-12-7 5-nitrobenzotriazole 
• 41939-61-1 N₁-methyl-4-nitrobenzene-1,2-diamine 
• 944718-31-4 5-bromo-1-methyl-1H-benzo[d][1,2,3]triazole 

Relevant academic research and scientific papers

Histone lysine methyltransferase NSD2 inhibiting small-molecule compound and application thereof

The invention belongs to the field of chemical medicine and particularly relates to a histone lysine methyltransferase NSD2 inhibiting small-molecule compound. A general formula of the small-moleculecompound is as shown in the specification. According to

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

Pyrazole compounds

Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

Summary -Reaction of various N-methyl-substituted 5-atninobenzazoles with ethoxymethylene derivatives of pentane-2,4-dione and 3-oxobutanoic acid

Reaction of 5-amino-l-methylbenzimidazole la, 5-amino-l-methylbenzotriazole Ib or 5-amino-2-methylbenzotriazole le with alkoxymethylene derivatives of pentane-2,4-dione, 3-oxobutanenitrile, methyl or ethyl 3-oxobutanoates yielded the products of nudeophilic substitution (3-6). The structures of derivatives 3-6 are discussed on the basis of their spectral characteristics: IR, UV, 1H NMR, 13C NMR and mass spectra. Elsevier.